NAS:AMPH (USA)
Business Description
Amphastar Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Compare
Compare
Traded in other countries / regions
29A.Germany
•
AMPH.USA
Description
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.77 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | 0.72 | |||||
| Interest Coverage | 65.97 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 6.23 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.5 | |||||
| 3-Year EBITDA Growth Rate | 148.1 | |||||
| 3-Year Book Growth Rate | 9.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.11 | |||||
| 9-Day RSI | 25.29 | |||||
| 14-Day RSI | 32.57 | |||||
| 6-1 Month Momentum % | 31.98 | |||||
| 12-1 Month Momentum % | 83.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.64 | |||||
| Quick Ratio | 2.69 | |||||
| Cash Ratio | 1.77 | |||||
| Days Inventory | 141.4 | |||||
| Days Sales Outstanding | 57.98 | |||||
| Days Payable | 36.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.51 | |||||
| Operating Margin % | 20.02 | |||||
| Net Margin % | 19.06 | |||||
| ROE % | 19.97 | |||||
| ROA % | 13.26 | |||||
| ROIC % | 17.51 | |||||
| ROC (Joel Greenblatt) % | 33.36 | |||||
| ROCE % | 20.53 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.76 | |||||
| PE Ratio without NRI | 17.76 | |||||
| Shiller PE Ratio | 16.72 | |||||
| Price-to-Owner-Earnings | 27.45 | |||||
| PEG Ratio | 0.53 | |||||
| PS Ratio | 3.4 | |||||
| PB Ratio | 3.1 | |||||
| Price-to-Tangible-Book | 3.36 | |||||
| Price-to-Free-Cash-Flow | 22.96 | |||||
| Price-to-Operating-Cash-Flow | 16.74 | |||||
| EV-to-EBIT | 12.41 | |||||
| EV-to-EBITDA | 10.12 | |||||
| EV-to-Revenue | 3.08 | |||||
| EV-to-FCF | 20.89 | |||||
| Price-to-Projected-FCF | 2.54 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.71 | |||||
| Price-to-Graham-Number | 1.63 | |||||
| Price-to-Net-Current-Asset-Value | 10.13 | |||||
| Earnings Yield (Greenblatt) % | 8.06 | |||||
| Forward Rate of Return (Yacktman) % | 21.39 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AMPH
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 476.92 | ||
| EPS (TTM) ($) | 1.78 | ||
| Beta | 0.49 | ||
| Volatility % | 40.04 | ||
| 14-Day RSI | 32.57 | ||
| 14-Day ATR ($) | 1.753624 | ||
| 20-Day SMA ($) | 35.8525 | ||
| 12-1 Month Momentum % | 83.41 | ||
| 52-Week Range ($) | 17.56 - 44.46 | ||
| Shares Outstanding (Mil) | 49.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amphastar Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||